Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro

• Published in: British journal of cancer Vol. 76; no. 8; pp. 1017 - 1020
• Main Authors: COLSTON, K. W, JAMES, S. Y, OFORI-KURAGU, E. A, BINDERUP, L, GRANT, A. G
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 01.10.1997
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - ultrastructure; Animals; Antineoplastic agents; Antineoplastic Agents - pharmacology; Biological and medical sciences; Calcitriol - analogs & derivatives; Calcitriol - pharmacology; Cell Division - drug effects; Chemotherapy; Dose-Response Relationship, Drug; Female; Humans; Medical sciences; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - ultrastructure; Pharmacology. Drug treatments; Receptors, Calcitriol - metabolism; Transplantation, Heterologous; Tumor Cells, Cultured - drug effects; Antineoplastic agent; Human; Animal model; Carcinoma; Rodentia; Malignant tumor; In vitro; In vivo; Vertebrata; Chemotherapy; Mammalia; Treatment; Mouse; Vitamin D; Analog; Animal; Established cell line; Digestive diseases; Pancreas; Pancreatic disease; Biological receptor
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.1997.501

The GER human pancreatic carcinoma cell line possesses receptors for 1,25-dihydroxyvitamin D3. We report that the vitamin D analogue EB 1089 inhibits the growth of these cells in vitro and when grown as tumour xenografts in immunodeficient mice. Tumour-bearing mice were given EB 1089 at a dose of 5 microg kg(-1) body weight i.p. thrice weekly for 4-6 weeks. Tumour growth was significantly inhibited in treated animals compared with controls in the absence of hypercalcaemia. These findings may have therapeutic implications in pancreatic cancer.